Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.

A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.